Share Name Share Symbol Market Type
Innate Pharma EU:IPH Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.026 0.81% 3.248 3.24 3.248 3.25 3.136 3.22 116,752 16:35:24

Innate Pharma Shares Slide After Failure of Monalizumab in Head, Neck Cancer

01/08/2022 11:30am

Dow Jones News

Innate Pharma (EU:IPH)
Historical Stock Chart

From Feb 2022 to Feb 2023

Click Here for more Innate Pharma Charts.

By Colin Kellaher


Shares of Innate Pharma SA tumbled sharply on Monday following the failure of the clinical-stage biotech company's lead partnered asset in a Phase 3 study in head and neck cancer.

The Marseille, France, company said the study evaluating monalizumab in combination with cetuximab versus cetuximab alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck didn't meet a pre-defined threshold for efficacy, and that partner AstraZeneca PLC was pulling the plug on the trial.

Innate, which has licensed full oncology rights to monalizumab to AstraZeneca under a 2015 development and commercialization agreement, said it remains confident in the development program for monalizumab in lung cancer.

Paris-listed shares of Innate were recently down 16% to EUR2.53, while its U.S.-listed shares fell 17% in premarket trading to $2.66.


Write to Colin Kellaher at


(END) Dow Jones Newswires

August 01, 2022 06:15 ET (10:15 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Innate Pharma Chart

1 Year Innate Pharma Chart

1 Month Innate Pharma Chart

1 Month Innate Pharma Chart
Your Recent History
Innate Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20230205 04:57:24